MGX vs. FENC, IVVD, BDTX, GLUE, AVXL, CHRS, STRO, OPT, IPSC, and CMPX
Should you be buying Metagenomi stock or one of its competitors? The main competitors of Metagenomi include Fennec Pharmaceuticals (FENC), Invivyd (IVVD), Black Diamond Therapeutics (BDTX), Monte Rosa Therapeutics (GLUE), Anavex Life Sciences (AVXL), Coherus BioSciences (CHRS), Sutro Biopharma (STRO), Opthea (OPT), Century Therapeutics (IPSC), and Compass Therapeutics (CMPX). These companies are all part of the "biological products, except diagnostic" industry.
Metagenomi (NASDAQ:MGX) and Fennec Pharmaceuticals (NASDAQ:FENC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.
Metagenomi presently has a consensus price target of $21.40, indicating a potential upside of 184.20%. Fennec Pharmaceuticals has a consensus price target of $17.33, indicating a potential upside of 88.20%. Given Metagenomi's higher probable upside, equities research analysts plainly believe Metagenomi is more favorable than Fennec Pharmaceuticals.
Metagenomi has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -75.50%.
Fennec Pharmaceuticals has lower revenue, but higher earnings than Metagenomi.
In the previous week, Fennec Pharmaceuticals had 5 more articles in the media than Metagenomi. MarketBeat recorded 6 mentions for Fennec Pharmaceuticals and 1 mentions for Metagenomi. Metagenomi's average media sentiment score of 1.02 beat Fennec Pharmaceuticals' score of 0.43 indicating that Metagenomi is being referred to more favorably in the media.
55.5% of Fennec Pharmaceuticals shares are held by institutional investors. 11.3% of Fennec Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Fennec Pharmaceuticals received 183 more outperform votes than Metagenomi when rated by MarketBeat users. However, 100.00% of users gave Metagenomi an outperform vote while only 65.29% of users gave Fennec Pharmaceuticals an outperform vote.
Summary
Metagenomi beats Fennec Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Get Metagenomi News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Metagenomi Competitors List
Related Companies and Tools
